Nanomedicine activation profile determines efficacy depending on tumor c-Myc expression

Nanomedicine activation profile determines efficacy depending on tumor c-Myc expression

style="display:inline-block;width:728px;height:90px" data-ad-client="ca-pub-1064213803427912" data-ad-slot="4222299391">

The half-life of a potent c-Myc inhibitor JQ1H was improved by encapsulating inside nanomicelles. Two types of nanomicelles were designed depending on the tumor acidity-driven activation; one is fast drug-releasing (FR-JQ1H/m), and another is slow releasing (SR-JQ1H/m). Anticancer activity study in mice revealed that FR-JQ1H/m was more effective in c-Myc high tumor, whereas SR-JQ1H/m was superior in c-Myc low tumor.

Comment at bottem of page

Leave a Reply